KUALA LUMPUR, Oct 20 (Bernama) -- United States women’s health company Hologic has signed a definitive agreement to acquire Reveal Genomics, a Barcelona-based precision oncology company that develops advanced genomic tests to help guide personalised cancer treatment.
Business : Hologic To Buy Spanish Breast Cancer Test Firm Reveal Genomics
Hologic To Buy Spanish Breast Cancer Test Firm Rev
BE Bernama 
Key points
- Reveal Genomics’ tests include HER2DX, which is designed to help optimise therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
- In a statement, Hologic said the tests complement its existing oncology diagnostics, including the Breast Cancer Index (BCI), a guideline-recognised genomic test that helps inform decisions on extended endocrine therapy for women with hormone receptor-positive (HR+) early-stage breast cancer.
- The company said the deal would significantly expand its diagnostic oncology portfolio, with the combined range of tests expected to help inform treatment decisions for more women with breast cancer.
Sentences selected automatically from the original article by Bernama.
Read the full story on Bernama That's the opening of the story. The full piece is published by Bernama.
Continue reading ↗ Story details
- Published
- Section
- news
- Format
- Article
- Original
- bernama.com ↗
Topics
Related reporting
3 stories on this topic from 2 sources, oldest first.
- Free Malaysia Today What can women really do to reduce breast cancer risk?
- Free Malaysia Today Homesoy, NCSM join forces to boost breast cancer screening
- Bernama Business : Hologic To Buy Spanish Breast Cancer Test Firm Reveal Genomics (this story)
%2Ffile%2Fattachments%2Forphans%2Ftest1_716667.png&w=480&output=webp&q=85&we)
